Clinical Trial Update: Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119) [Phase 3]

View source ↗

Summary

This report presents Phase 3 results from a trial evaluating once-daily oral roflumilast in adults over 40 with chronic obstructive pulmonary disease, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: COPD | Phase 3 | Status: COMPLETED